Haemonetics Corporation (HAE) Stock Score, Valuation & Financial Research
Haemonetics Corporation is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 30/100.
Quick answer for HAE
Haemonetics Corporation currently has a Wall Street Score of 30/100. The stored market price is $106.24. Its financial score is 20/100. Its valuation score is 0/100. The latest WSS change is -1.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Haemonetics Corporation does
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace T
HAE financial snapshot
- Wall Street Score:
- 30/100
- Current price:
- $106.24
- Market capitalization:
- $4.83B
- Revenue:
- $1.35B
- Net income:
- $96.3M
- Free cash flow:
- $260.4M
- Cash:
- $223.4M
- Total debt:
- $1.17B
- EPS:
- 2.05
- P/E ratio:
- 51.8x
- Financial score:
- 20/100
- Valuation score:
- 0/100
- Revenue score:
- 11/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $260.4M, showing positive cash generation.
- The balance sheet shows $223.4M of cash versus $1.17B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -1.1 points: HAE decreased 1.1 points because Capital declined by 7 points, Valuation declined by 5 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 20/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research HAE
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.